Bill C-64

Pharmacare Act

An Act respecting pharmacare

Sponsor

Mark Holland  Liberal

Status

In committee (Senate), as of June 18, 2024

Subscribe to a feed (what's a feed?) of speeches and votes in the House related to Bill C-64.

Summary

This is from the published bill. The Library of Parliament often publishes better independent summaries.

This enactment sets out the principles that the Minister of Health is to consider when working towards the implementation of national universal pharmacare and obliges the Minister to make payments, in certain circumstances, in relation to the coverage of certain prescription drugs and related products. It also sets out certain powers and obligations of the Minister — including in relation to the preparation of a list to inform the development of a national formulary and in relation to the development of a national bulk purchasing strategy — and requires the Minister to publish a pan-Canadian strategy regarding the appropriate use of prescription drugs and related products. Finally, it provides for the establishment of a committee of experts to make certain recommendations.

Elsewhere

All sorts of information on this bill is available at LEGISinfo, an excellent resource from the Library of Parliament. You can also read the full text of the bill.

Votes

June 3, 2024 Passed 3rd reading and adoption of Bill C-64, An Act respecting pharmacare
May 30, 2024 Passed Concurrence at report stage of Bill C-64, An Act respecting pharmacare
May 30, 2024 Failed Bill C-64, An Act respecting pharmacare (report stage amendment)
May 7, 2024 Passed 2nd reading of Bill C-64, An Act respecting pharmacare
May 7, 2024 Failed 2nd reading of Bill C-64, An Act respecting pharmacare (reasoned amendment)
May 6, 2024 Passed Time allocation for Bill C-64, An Act respecting pharmacare

Health Committee, on May 23, 2024

  • Daniel MacDonald, Director General, Office of Pharmaceuticals Management Strategies, Strategic Policy Branch, Department of Health
  • Michelle Boudreau, Associate Assistant Deputy Minister, Strategic Policy Branch, Department of Health
  • Jim Keon, President, Canadian Generic Pharmaceutical Association
  • Steven Staples, National Director, Policy and Advocacy, Canadian Health Coalition
  • Mike Bleskie, Advocate, Type 1 Diabetes, Canadian Health Coalition
  • Stephen Frank, President and Chief Executive Officer, Canadian Life and Health Insurance Association
  • Yves Giroux, Parliamentary Budget Officer, Office of the Parliamentary Budget Officer
  • Lisa Barkova, Analyst, Office of the Parliamentary Budget Officer
  • Joelle Walker, Vice-President, Public and Professional Affairs, Canadian Pharmacists Association
  • Manuel Arango, Vice-President, Policy and Advocacy, Heart and Stroke Foundation of Canada
  • Celeste Theriault, Executive Director, National Indigenous Diabetes Association Inc.
  • Diane Francoeur, Chief Executive Officer, Society of Obstetricians and Gynaecologists of Canada

Health Committee, on May 24, 2024

  • Angelique Berg, President and Chief Executive Officer, Canadian Association for Pharmacy Distribution Management
  • Linda Silas, President, Canadian Federation of Nurses Unions
  • Durhane Wong-Rieger, President and Chief Executive Officer, Canadian Organization for Rare Disorders
  • Jessica Diniz, President and Chief Executive Officer, JDRF Canada
  • Benoit Morin, President, Association québécoise des pharmaciens propriétaires
  • Bill VanGorder, Chief Policy Officer, Canadian Association of Retired Persons
  • Russell Williams, Senior Vice-President, Mission, Diabetes Canada
  • Carolyne Eagan, Principal Representative, Smart Health Benefits Coalition
  • Glenn Thibeault, Executive Director, Government Affairs, Advocacy and Policy, Diabetes Canada
  • Marc-André Gagnon, Associate Professor, School of Public Policy and Administration, Carleton University, As an Individual
  • Steven Morgan, Professor, School of Population and Public Health, University of British Columbia, As an Individual
  • Wendy Norman, Public Health Agency of Canada Chair, Family Planning Research, Action Canada for Sexual Health and Rights
  • John Adams, Board Chair, Best Medicines Coalition

Health Committee, on May 27, 2024

  • Émilie Thivierge, Legislative Clerk
  • Michelle Boudreau, Associate Assistant Deputy Minister, Strategic Policy Branch, Department of Health
  • Daniel MacDonald, Director General, Office of Pharmaceuticals Management Strategies, Strategic Policy Branch, Department of Health